* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Production and evaluation of FMDV stabilised capsids as potent, rapidly deployable vaccines, B. Charleston
Survey
Document related concepts
Human cytomegalovirus wikipedia , lookup
Bioterrorism wikipedia , lookup
Leptospirosis wikipedia , lookup
Whooping cough wikipedia , lookup
2015–16 Zika virus epidemic wikipedia , lookup
Influenza A virus wikipedia , lookup
Eradication of infectious diseases wikipedia , lookup
Middle East respiratory syndrome wikipedia , lookup
Ebola virus disease wikipedia , lookup
Orthohantavirus wikipedia , lookup
West Nile fever wikipedia , lookup
Antiviral drug wikipedia , lookup
Hepatitis B wikipedia , lookup
Marburg virus disease wikipedia , lookup
Transcript
Bryan Charleston Global Foot-and-mouth disease Research Alliance (GFRA): Production and evaluation of Foot-and-mouth disease virus stabilised capsids as potent, rapidly deployable vaccines “emergency vaccination should be seen as a major tool of first resort … for controlling FMD outbreaks” Royal Society Recombinant FMDV capsids Translation strategy – selectively reduce 3C translation 142C>T/S mRNA levels unaltered Baculovirus derived FMDV capsids Structure-based stabilisation of FMDV capsids Proof of principle that an engineered mutation (his to cys) is consistent with capsid assembly. Similar approaches can be used for infectious copies. Structure-based stabilisation of FMDV capsids Proof of principle that an engineered mutation (his to cys) is consistent with capsid assembly. Similar approaches can be used for infectious copies. Capsid production2 Wild-type and stable capsid structures2 Empty capsids with enhanced stability Cattle vaccinated with 12ug of Baculovirus derived FMDV capsids in commercial oil adjuvant Day 0 and Day 21 Stabilised empty capsids - Improved storage characteristics: vaccine ready for deployment, less reliant on cold chain - Safe production: no live virus required, enhanced production capacity - Vaccine can be produced to new virus variants: no need to isolate virus and adapt to tissue culture, sequence → gene synthesis → expression - Opportunities for further development: enhance early response, increased antigenic breadth - No non-structural proteins: companion DIVA diagnostic tests, greater certainty of discriminating between vaccinated and infected animals - Reagents for diagnostic test: safe production, improved shelf life Julian Seago Nick Juleff Terry Jackson Claudine Porta Dave Stuart Liz Fry Abhay Kotecha Francois Maree Belinda Blignaut Katherine Scott Pamela Opperman Elizabeth Rieder Sabena Uddowla Ian Jones